Trial reportCirculation2001
Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.
Trial report in Circulation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000463. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Post Coronary Artery Bypass Graft (CABG) Study
The Cardiac Protective Effect of Simvastatin on Cardiac Surgery: a Double Blind, Randomised Clinical Trial
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Preoperative statin therapy for adults undergoing cardiac surgery.The Cochrane database of systematic reviews · 2024Pooled it
- HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.The Cochrane database of systematic reviews · 2015Pooled it
- Alabama coronary artery bypass grafting project: results from phase II of a statewide quality improvement initiative.Annals of surgery · 2004Trial
- Association between patterns of circulating vitamin co-exposure and the prognosis of rheumatoid arthritis.Clinical rheumatology · 2026Article
- The prognostic role of the low and very low baseline LDL-C level in outcomes of patients with cardiac revascularization; comparative registry-based cohort design.Journal of cardiothoracic surgery · 2023Article
- The Clinical Outcomes Based on the Achievement of Low-Density Lipoprotein Cholesterol Targets after ST Elevation Myocardial Infarction.Journal of clinical medicine · 2019Article
- The Role of Statins in the Management of Patients Undergoing Coronary Artery Bypass Grafting.Diseases (Basel, Switzerland) · 2018Review
- Article
- Statins and vein graft failure in coronary bypass surgery.Current opinion in pharmacology · 2012Review
- Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG registry.The Canadian journal of cardiology · 2006Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Post Coronary Artery Bypass Graft Trial, designed to compare the effects of two lipid-lowering regimens and low-dose anticoagulation versus placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surgery, demonstrated that aggressive lowering of LDL cholesterol levels to a mean yearly cholesterol level from 93 to 97 mg/dL compared with a moderate reduction to a level of 132 to 136 mg/dL decreased the progression of atherosclerosis in saphenous vein grafts. Low-dose anticoagulation did not affect progression. This secondary analysis tested the hypothesis that a similar decrease in progression of atherosclerosis would also be present in native coronary arteries as measured in the left main coronary artery (LMCA). METHODS AND
resultsA sample of 402 patients was randomly selected from 1102 patients who had baseline and follow-up views of the LMCA suitable for analysis. Patients treated with the aggressive lipid-lowering strategy had less progression of atherosclerosis in the LMCA as measured by changes in minimum (P=0.0003) lumen diameter or the maximum percent stenosis (P=0.001), or the presence of substantial progression (P=0.008), or vascular occlusion (P=0.005) when compared with the moderate strategy.
conclusionsA strategy of aggressive lipid lowering results in significantly less atherosclerosis progression than a moderate approach in LMCAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.